ProfileGDS5678 / 1437258_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 71% 66% 66% 64% 65% 69% 67% 66% 65% 65% 66% 65% 67% 66% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.4888771
GSM967853U87-EV human glioblastoma xenograft - Control 23.9969866
GSM967854U87-EV human glioblastoma xenograft - Control 33.9784266
GSM967855U87-EV human glioblastoma xenograft - Control 43.8113864
GSM967856U87-EV human glioblastoma xenograft - Control 53.8982465
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.2723869
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0853967
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.9991366
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.9229165
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.8781665
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.9897666
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.8835965
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.0977967
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.0097966